Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants Dec 20, 2024
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu Dec 5, 2024
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments Nov 8, 2024
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock Oct 30, 2024
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock Oct 28, 2024
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate Oct 24, 2024
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 Oct 22, 2024
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers Oct 15, 2024
